Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection
作者： Wenjiang Zhang , Lillian L. Siu , Malcolm J. Moore , Eric X. Chen
DOI: 10.1016/J.JCHROMB.2004.10.016
关键词: Metabolite 、 Ether 、 Extraction (chemistry) 、 High-performance liquid chromatography 、 Chromatography 、 Spectrophotometry 、 Sample preparation 、 Potassium phosphate 、 Reproducibility 、 Chemistry
摘要: A new method was developed and validated for quantitating OSI-774 its metabolite OSI-420 in human plasma. Sample preparation involved initial extraction with methyl t-butyl ether followed by back HCl re-extraction ether. This process resulted significant improvement the specificity, reproducibility sensitivity. The analytes were separated on a Water Symmetry C18 analytical column mobile phase consisted of acetonitrile-0.05 M potassium phosphate buffer (42:58, v/v) (pH 4.8), monitored at wavelength 345 nm. Values between- within-day precision accuracy both <20%. successfully applied to study steady-state pharmacokinetics II clinical trial.
elsevier.com
sci-hub.se 参考文章(11)
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
Erin R. Lepper, Sandra M. Swain, Antoinette R. Tan, William D. Figg, Alex Sparreboom, Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor Journal of Chromatography B. ,vol. 796, pp. 181- 188 ,(2003) , 10.1016/J.JCHROMB.2003.08.015
J.R Woodburn, The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology & Therapeutics. ,vol. 82, pp. 241- 250 ,(1999) , 10.1016/S0163-7258(98)00045-X
Fortunato Ciardiello, Ferdinando De Vita, Michele Orditura, Sabino De Placido, Giampaolo Tortora, Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opinion on Emerging Drugs. ,vol. 8, pp. 501- 514 ,(2003) , 10.1517/14728214.8.2.501
Ming Zhao, Ping He, Michelle A. Rudek, Manuel Hidalgo, Sharyn D. Baker, Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. ,vol. 793, pp. 413- 420 ,(2003) , 10.1016/S1570-0232(03)00356-8
David S. Salomon, Ralf Brandt, Fortunato Ciardiello, Nicola Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies Critical Reviews in Oncology Hematology. ,vol. 19, pp. 183- 232 ,(1995) , 10.1016/1040-8428(94)00144-I
Maarten L. Janmaat, Giuseppe Giaccone, Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist. ,vol. 8, pp. 576- 586 ,(2003) , 10.1634/THEONCOLOGIST.8-6-576
Denis Soulieres, Neil N. Senzer, Everett E. Vokes, Manuel Hidalgo, Sanjiv S. Agarwala, Lillian L. Siu, Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Journal of Clinical Oncology. ,vol. 22, pp. 77- 85 ,(2004) , 10.1200/JCO.2004.06.075
Roy S. Herbst, Paul A. Bunn, Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clinical Cancer Research. ,vol. 9, pp. 5813- 5824 ,(2003)
Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Jinee Rizzo, Lisa A. Hammond, Chris Takimoto, S. Gail Eckhardt, Anthony Tolcher, Carolyn D. Britten, Louis Denis, Karen Ferrante, Daniel D. Von Hoff, Sandra Silberman, Eric K. Rowinsky, Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Journal of Clinical Oncology. ,vol. 19, pp. 3267- 3279 ,(2001) , 10.1200/JCO.2001.19.13.3267